Diabetes Care, Vol 19, Issue 11 1190-1193, Copyright © 1996 by American Diabetes Association

ARTICLES

The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance

JL Chiasson, RG Josse, LA Leiter, M Mihic, DM Nathan, C Palmason, RM Cohen and TM Wolever
Research Center, Hotel-Dieu de Montreal, Toronto, Canada. chiassoj@ere.montreal.ca

OBJECTIVE: To study the effect of acarbose, an alpha-glucosidase inhibitor, on postprandial plasma glucose and insulin and insulin sensitivity in subjects with impaired glucose tolerance (IGT). RESEARCH DESIGN AND METHODS: Subjects with IGT were randomly treated in a double-blind fashion with placebo (n = 10) or acarbose (n = 8) at 100 mg t.i.d. for 4 months. All subjects were submitted before randomization and at the end of the study to a standardized breakfast and a 12-h daytime plasma glucose and plasma insulin profile, and insulin sensitivity was measured as steady-state plasma glucose (SSPG) using the insulin suppression test. RESULTS: While placebo had no effect on postprandial plasma glucose and plasma insulin incremental area under the curve (AUC) (3.03 +/- 0.5 vs. 3.76 +/- 0.6 mmol.h-1.l-1, P = NS; 1,488 +/- 229 vs. 1,609 +/- 253 pmol.h-1.l-1, P = NS), acarbose resulted in a significant reduction for both glucose (1.44 +/- 0.3 vs. 4.45 +/- 0.9 mmol.h-1.l-1, P = 0.002) and insulin (626.7 +/- 104.3 vs. 1,338.3 +/- 220.5 pmol.h-1.l-1, P = 0.003). The reduction in 12-h plasma glucose and insulin AUC on acarbose (11.2 +/- 2.1 mmol.h-1.l-1 and 7.5 +/- 0.7 nmol.h-1.l-1) was significantly greater than that on placebo (4.0 +/- 1.6 mmol.h-1.l-1 and 0.8 +/- 0.4 nmol.h-1.l-1) (P = 0.014 and 0.041). While SSPG was not affected by placebo (13.9 +/- 0.4 vs. 13.8 +/- 0.3 mmol/l; P = NS), it was significantly improved by acarbose (10.9 +/- 1.4 vs. 13.1 +/- 1.5 mmol/l, P < 0.004) and was also significantly different from placebo at 4 months (P < 0.02). CONCLUSIONS: It is concluded that in subjects with IGT, acarbose treatment decreases postprandial plasma glucose and insulin and improves insulin sensitivity. Acarbose may therefore be potentially useful to prevent the progression of IGT to NIDDM.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. W. Chia and J. M. Egan Incretin-Based Therapies in Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3703 - 3716. [Abstract] [Full Text] [PDF]

				H. Wagner, M. Degerblad, A. Thorell, J. Nygren, A. Stahle, J. Kuhl, T. B. Brismar, J. Ohrvik, S. Efendic, and P. N. Bavenholm Combined Treatment With Exercise Training and Acarbose Improves Metabolic Control and Cardiovascular Risk Factor Profile in Subjects With Mild Type 2 Diabetes Diabetes Care, July 1, 2006; 29(7): 1471 - 1477. [Abstract] [Full Text] [PDF]

				I.A.A. Penna, P.R.B. Canella, R.M. Reis, M.F. Silva de Sa, and R.A. Ferriani Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study Hum. Reprod., September 1, 2005; 20(9): 2396 - 2401. [Abstract] [Full Text] [PDF]

				D. C Anderson Jr Pharmacologic Prevention or Delay of Type 2 Diabetes Mellitus Ann. Pharmacother., January 1, 2005; 39(1): 102 - 109. [Abstract] [Full Text] [PDF]

				A. M. Chang, M. J. Smith, C. J. Bloem, A. T. Galecki, and J. B. Halter Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance Am J Physiol Endocrinol Metab, November 1, 2004; 287(5): E906 - E911. [Abstract] [Full Text] [PDF]

				T. M.S. Wolever, J. E. Campbell, D. Geleva, and G. H. Anderson High-Fiber Cereal Reduces Postprandial Insulin Responses in Hyperinsulinemic but not Normoinsulinemic Subjects Diabetes Care, June 1, 2004; 27(6): 1281 - 1285. [Abstract] [Full Text] [PDF]

				V. De Leo, A. la Marca, and F. Petraglia Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome Endocr. Rev., October 1, 2003; 24(5): 633 - 667. [Abstract] [Full Text] [PDF]

				J.-L. Chiasson, R. G. Josse, R. Gomis, M. Hanefeld, A. Karasik, and M. Laakso Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance: The STOP-NIDDM Trial JAMA, July 23, 2003; 290(4): 486 - 494. [Abstract] [Full Text] [PDF]

				T. M. Wolever and C. Mehling Long-term effect of varying the source or amount of dietary carbohydrate on postprandial plasma glucose, insulin, triacylglycerol, and free fatty acid concentrations in subjects with impaired glucose tolerance Am. J. Clinical Nutrition, March 1, 2003; 77(3): 612 - 621. [Abstract] [Full Text] [PDF]

				S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring Pathophysiology and Pharmacological Treatment of Insulin Resistance Endocr. Rev., December 1, 2000; 21(6): 585 - 618. [Abstract] [Full Text]

				S. M. Haffner The Importance of Hyperglycemia in the Nonfasting State to the Development of Cardiovascular Disease Endocr. Rev., October 1, 1998; 19(5): 583 - 592. [Abstract] [Full Text]